← Back to guidelines
Cardiology59 papers

Light chain nephropathy

Last edited: 4/14/2026

Overview

Light chain nephropathy results from the deposition of misfolded light chains, typically derived from clonal plasma cells, leading to renal dysfunction and damage 3.

Diagnosis

  • Key Diagnostic Criteria: Presence of monoclonal light chains in urine or blood, renal biopsy showing amyloid deposits 3.
  • Recommended Tests: Urine and serum protein electrophoresis (UPEP, SPE), free light chain (FLC) assay, renal biopsy 1.
  • Grading: Utilize biomarkers for prognostic stratification and organ involvement assessment 1.
  • Management

  • First-Line Treatments: Chemotherapy regimens such as bortezomib-based therapy, often combined with immunomodulatory drugs (IMiDs) like lenalidomide or dexamethasone 1.
  • Adjunctive Treatments: Dialysis or renal replacement therapy for severe renal failure 3.
  • Specific Drug Classes: Bortezomib, lenalidomide, dexamethasone (doses vary based on clinical trial protocols and patient tolerance) 1.
  • Special Populations

  • Comorbidities: Cardiac involvement may require specialized management, such as ECMO support in acute heart failure scenarios 2.
  • Key Recommendations

  • Tailor treatment strategies using biomarker-based response criteria for precise prognostic stratification and therapeutic adjustments (Evidence: Strong 1).
  • Consider extracorporeal membrane oxygenation (ECMO) as a bridge-to-decision in acute heart failure cases due to systemic light-chain amyloidosis (Evidence: Weak 2).
  • Employ chemotherapy regimens including bortezomib for systemic light chain amyloidosis to target the underlying plasma cell dyscrasia (Evidence: Strong 1).
  • References

    1 Palladini G, Milani P. Individualized Approach to Management of Light Chain Amyloidosis. Journal of the National Comprehensive Cancer Network : JNCCN 2023. link 2 Mancio Silva J, Fontes-Carvalho R, Valente D, Almeida C, Cruz AJ, Tente D et al.. Extracorporeal membrane oxygenation as bridge-to-decision in acute heart failure due to systemic light-chain amyloidosis. The American journal of case reports 2015. link 3 Yaqoob M, Bell GM, Davies JM, McDicken IW. Light chain nephropathy. Case report. Scandinavian journal of urology and nephrology 1992. link 4 Duvoisin RM, Kocher HP, Garcia I, Rougeon F, Jaton JC. Nucleotide sequence of a cDNA encoding the constant region of a rabbit immunoglobulin light chain of the lambda type. European journal of immunology 1984. link

    Original source

    1. [1]
      Individualized Approach to Management of Light Chain Amyloidosis.Palladini G, Milani P Journal of the National Comprehensive Cancer Network : JNCCN (2023)
    2. [2]
      Extracorporeal membrane oxygenation as bridge-to-decision in acute heart failure due to systemic light-chain amyloidosis.Mancio Silva J, Fontes-Carvalho R, Valente D, Almeida C, Cruz AJ, Tente D et al. The American journal of case reports (2015)
    3. [3]
      Light chain nephropathy. Case report.Yaqoob M, Bell GM, Davies JM, McDicken IW Scandinavian journal of urology and nephrology (1992)
    4. [4]
      Nucleotide sequence of a cDNA encoding the constant region of a rabbit immunoglobulin light chain of the lambda type.Duvoisin RM, Kocher HP, Garcia I, Rougeon F, Jaton JC European journal of immunology (1984)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG